8-K: GeneDx Exceeds 2025 Targets, Forecasts Strong 2026 Growth

GeneDx Holdings Corp. announced preliminary 2025 financial results at the high end of or exceeding guidance and issued robust growth projections for 2026.

Summary

• GeneDx reported preliminary, unaudited full year 2025 revenues of approximately $427 million, a 41% increase year-over-year, meeting the high end of its previously raised guidance.
• Fourth quarter 2025 revenues reached approximately $121 million, marking a 27% year-over-year increase.
• Full year 2025 exome and genome revenues were approximately $360 million, up 54% year-over-year (58% excluding a one-time 2024 benefit), aligning with the high end of previous guidance.
• Exome and genome test result volume for full year 2025 was 97,271, an increase of 30.5% year-over-year, exceeding the guidance of at least 30% growth.
• Full year 2025 adjusted gross margin was approximately 71%, at the high end of the 70% to 71% guidance.
• The company held approximately $172 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2025.
• GeneDx issued full year 2026 guidance, expecting revenues between $540 and $555 million, with exome and genome revenue and volume growth projected at 33% to 35%, and positive adjusted net income.

Sentiment

Score: 9

Explanation: The filing presents strong preliminary financial results for 2025, meeting or exceeding previous guidance, coupled with robust and positive guidance for 2026, including projected profitability. Significant strategic advancements, market expansion, and leadership appointments further reinforce a highly positive outlook for the company's growth and market position.

Positives

• Full year 2025 revenue of $427 million met the high end of the previously raised guidance range ($425-$428 million).
• Full year 2025 exome and genome revenue growth of 54% (58% excluding a one-time 2024 benefit) was at the high end of the 53%-55% guidance.
• Full year 2025 exome and genome volume growth of 30.5% exceeded the guidance of 'at least 30% growth'.
• Full year 2025 adjusted gross margin of 71% was at the high end of the 70%-71% guidance.
• Strong 2026 guidance projects continued high growth with revenues of $540-$555 million and 33%-35% exome and genome growth.
• Expectation of positive adjusted net income for full year 2026, indicating a path to profitability.
• Launched GeneDx Infinity, the world's largest and most diverse rare disease genomic dataset, enhancing diagnostic capabilities.
• Expanded into new significant markets including general pediatrics, prenatal diagnostics, and ultraRapid genome sequencing.
• Secured Medicaid coverage for exome and genome sequencing in 8 new states, increasing total coverage to 37 states for pediatric outpatient and 17 states for rapid genome sequencing in NICU.
• Received FDA Breakthrough Device designation for ExomeDx and GenomeDx, validating their clinical significance.
• Acquired Fabric Genomics, expanding global delivery of genomic insights.
• Active participation and leadership in genomic newborn screening initiatives (BEACONS, Sunshine Genetics Network, GUARDIAN study).
• Strong financial position with approximately $172 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2025.

Risks

• Ability to implement business plans, goals, and forecasts, and identify and realize additional opportunities.
• Risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry.
• The size and growth of the market in which the company operates.
• Ability to pursue its new strategic direction.
• Actual future events could differ materially from forward-looking statements due to various factors.

Future Outlook

GeneDx anticipates accelerating growth into 2026, driven by its GeneDx Infinity platform and AI-driven technology. The company expects full year 2026 revenues between $540 and $555 million, with exome and genome revenue and volume growth of 33% to 35%, and projects positive adjusted net income. Strategic focus includes scaling across care settings, international expansion, deepening partnerships, and investing in data and expertise to define the next era of precision medicine.

Management Comments

• "In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment families need answers. In doing so, we delivered on our commitment to high growth and profitability, thanks to the relentless commitment of our team." Katherine Stueland, President and CEO.
• "As we enter 2026, GeneDx is accelerating. Powered by GeneDx Infinity – the worlds largest rare disease genomic dataset – and our AIdriven platform, we are positioned for durable, profitable growth over the next several years while accelerating diagnoses for patients around the world." Katherine Stueland, President and CEO.
• "We delivered on our commitment to drive more than 30% growth for the year with volume growth rates accelerating each quarter. Accessioning more than 30,000 patients in the fourth quarter, we are demonstrating the power and momentum of our data, scale advantage, and commercial strength to drive sustained high growth and an attractive gross margin profile." Kevin Feeley, CFO.
• "As we look to 2026, we are operating from a position of financial strength, allowing us to invest in our commercial engine and innovation pipeline to open new markets and fuel high growth – expected to be 33% to 35% in 2026 – and an industry-leading business well into the future." Kevin Feeley, CFO.

Industry Context

GeneDx operates in the rapidly evolving genomic medicine industry, focusing on rare disease diagnosis. The company's strategic expansion into general pediatrics and prenatal diagnostics aligns with broader trends towards earlier and more widespread adoption of genomic testing. The American Academy of Pediatrics' updated guidance recommending exome and genome sequencing as first-tier tests for children with developmental delays signifies a significant shift in standard of care, creating a larger addressable market. GeneDx's emphasis on AI-driven platforms and large datasets like GeneDx Infinity positions it at the forefront of leveraging technology for enhanced diagnostic accuracy and efficiency, a key competitive differentiator in the precision medicine landscape.

Comparison to Industry Standards

• GeneDx claims to be the global leader in rare disease diagnosis, with its ExomeDx and GenomeDx tests ranked #1 by expert geneticists and granted FDA Breakthrough Device designation.
• GeneDx Infinity is touted as the world's largest and most diverse rare disease genomic dataset, providing 2x the answers compared to public datasets, giving the company a significant scale advantage.
• The company reports 80% market share among geneticists, driven by superior accuracy, broad access, and cutting-edge discovery, indicating strong preference within a key customer segment.
• GeneDx has deep relationships, with 42 of the top 50 NICUs ordering rapid testing from them in 2025, demonstrating strong penetration in critical care settings.
• The company is contracted with 80% of covered lives, including all large national commercial payers, suggesting broad market access and reimbursement compared to industry peers.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Positive impact due to strong preliminary 2025 results, exceeding guidance, and robust 2026 growth projections, including expected positive adjusted net income, which could lead to increased share value.
• **Employees**: Positive impact from company growth, strategic expansion, and leadership strengthening, potentially leading to more opportunities and stability.
• **Customers (Patients/Families)**: Highly positive impact through accelerated diagnoses, expanded access to genomic testing (pediatrics, prenatal, ultraRapid), and enhanced diagnostic accuracy via GeneDx Infinity and AI tools.
• **Healthcare Providers (Geneticists, Pediatricians, NICU/PICU staff)**: Positive impact through improved diagnostic tools, expanded payer coverage, and streamlined workflows, enabling better patient care and clinical decision-making.
• **Payers**: Potential for long-term cost reduction through earlier, more accurate diagnoses leading to effective, targeted treatments and value-based care models.
• **Biopharma Partners**: Positive impact through enhanced data and AI-driven discovery capabilities via GeneDx Infinity, accelerating drug development and unlocking biomarkers.

Next Steps

• Katherine Stueland, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• GeneDx will release full financial results for the fourth quarter and full year of 2025 before the market opens on Monday, February 23, 2026.
• Management will host a conference call on February 23, 2026, at 8:30 a.m. Eastern Time to discuss financial and operating results.

Key Dates

Recommendation

GeneDx delivered preliminary 2025 results that met or exceeded its own raised guidance across key financial metrics, demonstrating strong operational execution and market traction. The robust 2026 guidance, projecting significant revenue and volume growth (33-35%) alongside positive adjusted net income, signals a clear path to sustained profitability and market leadership. Strategic initiatives like the launch of GeneDx Infinity, expansion into high-growth markets (pediatrics, prenatal), increased payer coverage, and FDA Breakthrough Device designation solidify its competitive advantage. The company's strong cash position supports continued investment in innovation and commercial expansion. These factors collectively present a compelling investment case for significant upside potential.

Keywords

Genomics, Rare Disease, Exome Sequencing, Genome Sequencing, Financial Results, 2026 Guidance, GeneDx Infinity, Precision Medicine, Pediatric Care, Prenatal Diagnostics, FDA Breakthrough Device, Newborn Screening, Healthcare Technology